| Literature DB >> 21838923 |
Hangxing Ren1, Li Li, Hongwei Su, Lingyang Xu, Caihong Wei, Li Zhang, Hongbin Li, Wenzhong Liu, Lixin Du.
Abstract
BACKGROUND: Whether myofibers increase with a pulsed-wave mode at particular developmental stages or whether they augment evenly across developmental stages in large mammals is unclear. Additionally, the molecular mechanisms of myostatin in myofiber hyperplasia at the fetal stage in sheep remain unknown. Using the first specialized transcriptome-wide sheep oligo DNA microarray and histological methods, we investigated the gene expression profile and histological characteristics of developing fetal ovine longissimus muscle in Texel sheep (high muscle and low fat), as a myostatin model of natural mutation, and Ujumqin sheep (low muscle and high fat). Fetal skeletal muscles were sampled at 70, 85, 100, 120, and 135 d of gestation.Entities:
Mesh:
Year: 2011 PMID: 21838923 PMCID: PMC3173453 DOI: 10.1186/1471-2164-12-411
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Changes in muscle fiber diameter throughout the five developmental stages in Texel and Ujumqin sheep. Longissimus dorsi muscle fiber diameter was examined in cross sections using hematoxylin and eosin staining. At least three animals were used to analyze each development stage in each breed. Photomicrographs of five to eight randomly selected areas were used to calculate the diameter of myofibers in each cross section of muscle examined.
Figure 2Changes in muscle fiber number throughout the five developmental stages in Texel and Ujumqin sheep. Longissimus dorsi muscle fiber number was examined in cross sections using hematoxylin and eosin staining. At least three animals were used to analyze each development stage in each breed. Photomicrographs of five to eight randomly selected areas were used to calculate the total number of myofibers in each cross section of muscle examined.
Figure 3Identification of Pax7-positive cells in longissimus dorsi muscle by immunofluorescence staining. Longissimus tissue sections were stained with fluorescent antibodies Pax7 (green) and laminin (red) at 135 d of gestation, respectively. A-D are the same frozen section stained with the two different fluorescent antibodies (400×). The corresponding antigens in muscle are indicated by an arrow (Pax7) and an arrowhead (laminin).
Figure 4Hierarchical clustering between the differentially expressed genes and individuals from the two sheep breeds. Clustering was performed using GeneSpring 10.0. A one-way analysis of variance was applied to two within-breed contrasts across developmental time. A pool of the differentially expressed probes from the two groups was used for system hierarchical clustering to clarify the transcriptome-wide similarities among all 31 individuals investigated.
Figure 5MA plot for differential genes in Texel and Ujumqin sheep. Genes expressed more highly in Ujumqin sheep are on the bottom, and genes expressed more highly in Texel sheep are on top. Genes involved in muscles, lipids, and the immune system are denoted by blue triangles, green circles, and red rectangles, respectively. For example, HLA-DQB1 and AR were highly expressed in Texel, whereas MYL6B was highly expressed in Ujumqin sheep. Other genes expressed differentially are denoted by gray rectangles.
Figure 6Abundance of primary functional clustering of differentially expressed genes. Counts of genes involved in muscles, lipids, and the immune system are represented by the ratio of functional categories relative to the total number of genes that exists in the microarray chip for each of those categories, respectively. The ratio illustrates the abundance of different clusters of differentially expressed genes between Texel and Ujumqin sheep at five developmental stages (70, 85, 100, 120, and 135 d of gestation).
Summary of the differentially expressed genes between T70 and U70 using IPA
| Top Bio Functions | ||
|---|---|---|
| Diseases and Disorders | ||
| Name | p-value1 | Molecules2 |
| 5.82E-08-.93E-03 | 51 | |
| 2.61E-06-7.93E-03 | 19 | |
| Developmental Disorder | 2.61E-06-7.93E-03 | 12 |
| Hypersensitivity Response | 8.91E-06-7.93E-03 | 8 |
| Inflammatory Response | 1.05E-05-7.93E-03 | 25 |
| Cell-To-Cell Signaling and Interaction | 1.77E-06-7.93E-03 | 32 |
| Cellular Movement | 8.91E-06-7.93E-03 | 25 |
| Lipid Metabolism | 9.16E-06-7.93E-03 | 25 |
| Molecular Transport | 9.16E-06-7.93E-03 | 28 |
| Small Molecule Biochemistry | 9.16E-06-7.93E-03 | 30 |
| Tissue Development | 1.77E-06-7.93E-03 | 24 |
| Hematological System Development and Function | 7.13E-06-7.93E-03 | 22 |
| Hematopoiesis | 8.91E-06-7.93E-03 | 9 |
| Immune Cell Trafficking | 8.91E-06-7.93E-03 | 19 |
| Skeletal and Muscular System Development and Function | 2.68E-05-7.93E-03 | 18 |
| Acute Phase Response Signaling | 2.2E-03 | 6/178 (0.034) |
| Glycolysis/Gluconeogenesis | 7.65E-03 | 4/142 (0.028) |
| 9.44E-03 | 3/93 (0.032) | |
| Calcium Signaling | 1.17E-02 | 5/204 (0.025) |
| CXCR4 Signaling | 3.31-02 | 4/169 (0.024) |
1. The p-value was calculated using a right-tailed Fisher's exact test. 2. The number of genes enriched in corresponding functions. 3. The ratio was calculated as the number of genes from our data set that overlap with the canonical pathway in question divided by the total number of genes represented in that canonical pathway.
4. Italicized terms such as "Cancer" and "Cardiovascular Disease" represent a biased annotation or are not related to the aim of the study.
IPA version: 8.7 (release date: 09-17-2010)
Content version: 3202 (release date: 07-07-2010)
Reference set: Ingenuity knowledge base (genes only)
Relationships to include: direct and indirect
Includes endogenous chemicals
Filter summary: Consider all molecules and/or relationships
Summary of the differentially expressed genes between T85 and U85 using IPA
| Top Bio Functions | ||
|---|---|---|
| Diseases and Disorders | ||
| Name | p-value1 | Molecules2 |
| 2.37E-07-1.98E-02 | 35 | |
| Inflammatory Response | 3.15E-06-2.00E-02 | 23 |
| Developmental Disorder | 1.37E-05-1.94E-02 | 8 |
| Skeletal and Muscular Disorder | 5.76E-05-1.85E-02 | 33 |
| Genetic Disorder | 5.77E-05-2.00E-02 | 54 |
| Cell-To-Cell Signaling and Interaction | 3.46E-05-2.00E-02 | 23 |
| Lipid Metabolism | 2.49E-04-2.00E-02 | 16 |
| Molecular Transport | 2.49E-04-2.00E-02 | 14 |
| Small Molecule Biochemistry | 2.49E-04-2.00E-02 | 18 |
| 3.71E-04-2.00E-02 | 5 | |
| Hematological System Development and Function | 3.46E-05-2.00E-02 | 17 |
| 3.71E-04-1.98E-02 | 5 | |
| 3.71E-04-3.71E-04 | 2 | |
| Hematopoiesis | 3.72E-04-2.00E-02 | 8 |
| Immune Cell Trafficking | 3.72E-04-1.98E-02 | 16 |
| Glycolysis/Gluconeogenesis | 1.34E-04 | 5/142 (0.035) |
| Fructose and Mannose Metabolism | 2.19E-04 | 4/145 (0.028) |
| Pentose Phosphate Pathway | 9.13E-04 | 3/89 (0.034) |
| Dendritic Cell Maturation | 1.31E-03 | 5/188 (0.027) |
| VEGF Signaling | 9.55E-03 | 3/99 (0.03) |
Symbols and analytical settings are the same as in Table 1.
Summary of differentially expressed genes between T100 and U100 using IPA
| Top Bio Functions | ||
|---|---|---|
| Diseases and Disorders | ||
| Name | p-value1 | Molecules2 |
| 7.71E-05-2.60E-02 | 3 | |
| Metabolic Disease | 1.05E-04-2.51E-02 | 8 |
| Hypersensitivity Response | 2.08E-04-2.51E-02 | 3 |
| Inflammatory Response | 2.08E-04-3.57E-02 | 11 |
| 5.03E-04-1.92E-02 | 14 | |
| Lipid Metabolism | 2.91E-11-3.57E-02 | 16 |
| Small Molecule Biochemistry | 2.91E-11-3.57E-02 | 21 |
| Vitamin and Mineral Metabolism | 2.91E-11-2.60E-02 | 16 |
| Molecular Transport | 8.41E-06-3.57E-02 | 19 |
| Cellular Movement | 2.08E-04-3.57E-02 | 5 |
| Hematological System Development and Function | 2.08E-04-3.57E-02 | 11 |
| Immune Cell Trafficking | 2.08E-04-3.57E-02 | 9 |
| Lymphoid Tissue Structure and Development | 2.08E-04-3.57E-02 | 4 |
| Tissue Development | 4.79E-04-3.57E-02 | 9 |
| Hematopoiesis | 6.96E-04-3.57E-02 | 6 |
| T-Helper Cell Differentiation | 2E-03 | 3/72 (0.042) |
| Inositol Metabolism | 3.73E-03 | 3/97 (0.031) |
| Biosynthesis of Steroids | 5.98E-03 | 2/128 (0.016) |
| EIF2 Signaling | 3.89E-02 | 2/103(0.019) |
| VEGF Signaling | 3.98E-02 | 2/99 (0.02) |
Symbols and analytical settings are the same as in Table 1.
Summary of differentially expressed genes between T120 and U120 using IPA
| Top Bio Functions | ||
|---|---|---|
| Diseases and Disorders | ||
| Name | p-value1 | Molecules2 |
| Hypersensitivity Response | 9.54E-06-1.19E-02 | 7 |
| Inflammatory Response | 9.54E-06-1.19E-02 | 18 |
| 3.78E-05-1.19E-02 | 41 | |
| Hematological Disease | 5.66E-05-1.19E-02 | 7 |
| Immunological Disease | 5.66E-05-1.19E-02 | 7 |
| Cell-To-Cell Signaling and Interaction | 9.54E-06-1.19E-02 | 17 |
| Lipid Metabolism | 1.16E-05-1.19E-02 | 16 |
| Small Molecule Biochemistry | 1.16E-05-1.19E-02 | 20 |
| Carbohydrate Metabolism | 3.54E-05-1.19E-02 | 5 |
| 3.54E-05-1.19E-02 | 10 | |
| Hematological System Development and Function | 9.54E-06-1.19E-02 | 23 |
| Immune Cell Trafficking | 9.54E-06-1.19E-02 | 13 |
| Nervous System Development and Function | 1.69E-05-1.19E-02 | 8 |
| Tissue Development | 1.69E-05-1.19E-02 | 13 |
| 7.17E-05-1.19E-02 | 10 | |
| 1.54E-04 | 5/91 (0.055) | |
| NF-kB Signaling | 1.87E-03 | 5/155 (0.032) |
| Autoimmune Thyroid Disease Signaling | 2.77E-03 | 3/61 (0.049) |
| 2.92E-03 | 4/113 (0.035) | |
| Taurine and Hypotaurine Metabolism | 3.53E-03 | 2/47 (0.043) |
Symbols and analytical settings are the same as in Table 1.
Summary of differentially expressed genes between T135 and U135 using IPA
| Top Bio Functions | ||
|---|---|---|
| Diseases and Disorders | ||
| Name | p-value1 | Molecules2 |
| 9.23E-06-2.87E-02 | 7 | |
| 9.23E-06-6.44E-03 | 7 | |
| Genetic Disorder | 3.22E-03-2.87E-02 | 5 |
| Immunological Disease | 3.22E-03-3.22E-03 | 1 |
| Infection Mechanism | 3.22E-03-4.11E-02 | 4 |
| Cell Cycle | 5.50E-04-2.87E-02 | 3 |
| Cell Death | 1.04E-03-2.43E-02 | 8 |
| Cell-To-Cell Signaling and Interaction | 3.22E-03-4.42E-02 | 5 |
| Cellular Assembly and Organization | 3.22E-03-4.42E-02 | 7 |
| Cellular Compromise | 3.22E-03-4.42E-02 | 3 |
| Embryonic Development | 5.50E-04-2.55E-02 | 5 |
| Tissue Development | 5.50E-04-4.11E-02 | 7 |
| Hematological System Development and Function | 2.47E-03-4.42E-02 | 7 |
| Cell-mediated Immune Response | 3.22E-03-4.42E-02 | 2 |
| Nervous System Development and Function | 3.22E-03-6.44E-03 | 2 |
| LPS/IL-1-mediated Inhibition of RXR Function | 3.61E-03 | 4/216 (0.019) |
| Histidine Metabolism | 1.26E-02 | 2/120 (0.017) |
| PXR/RXR Activation | 2.2E-02 | 2/91 (0.022) |
| Arginine and Proline Metabolism | 2.68E-02 | 2/183 (0.011) |
| Glycerolipid Metabolism | 4.51E-02 | 2/156 (0.013) |
Symbols and analytical settings are the same as in Table 1.
Examples of downregulated genes between Texel and Ujumqin sheep at the same developmental stage
| Probe Name | Genbank Accession Number | Gene | Fold | Developmental |
|---|---|---|---|---|
| A_70_P069356 | 15.35 | 70 d | ||
| A_70_P016291 | 5.16 | 70 d | ||
| A_70_P006561 | 4.54 | 70 d | ||
| A_70_P004621 | 2.38 | 70 d | ||
| A_70_P001706 | 2.28 | 70 d | ||
| A_70_P056812 | 2.24 | 70 d | ||
| A_70_P005526 | 8.23 | 85 d | ||
| A_70_P016291 | 5.99 | 85 d | ||
| A_70_P068196 | 5.19 | 85 d | ||
| A_70_P039551 | 5.00 | 85 d | ||
| A_70_P037096 | 2.77 | 85 d | ||
| A_70_P001731 | 8.04 | 100 d | ||
| A_70_P017916 | 8.03 | 100 d | ||
| A_70_P032741 | 7.09 | 100 d | ||
| A_70_P001411 | 5.59 | 100 d | ||
| A_70_P039326 | 4.50 | 100 d | ||
| A_70_P045271 | 4.01 | 100 d | ||
| A_70_P068131 | 2.23 | 100 d | ||
| A_70_P035741 | 65.59 | 120 d | ||
| A_70_P005526 | 21.27 | 120 d | ||
| A_70_P018856 | 15.37 | 120 d | ||
| A_70_P024811 | 7.16 | 120 d | ||
| A_70_P019481 | 4.92 | 120 d | ||
| A_70_P030147 | 4.84 | 120 d | ||
| A_70_P025536 | 4.62 | 120 d | ||
| A_70_P051317 | 4.46 | 120 d | ||
| A_70_P030402 | 4.37 | 120 d | ||
| A_70_P051037 | 8.14 | 135 d | ||
| A_70_P035536 | 5.37 | 135 d | ||
| A_70_P016291 | 4.14 | 135 d |
Differentially expressed probes were detected from five t-test analyses using GeneSpring 10.0 (Agilent Technologies).
1. Original probe name in microarray analysis. 2. GenBank Accession Number of expressed sequence tags provided by the manufacturer according to the specific probe name. 3. The highly homologous human sequences acquired using BLASTN search in NCBI (search setting: query coverage not less than 50%, E-value less than 1.00E-100).
Examples of upregulated genes between Texel and Ujumqin sheep at the same developmental stage
| Probe Name1 | GenBank2 Accession Number | Gene3 | Fold | Developmental |
|---|---|---|---|---|
| A_70_P046666 | 8.92 | 70 d | ||
| A_70_P011966 | 6.74 | 70 d | ||
| A_70_P019721 | 6.64 | 70 d | ||
| A_70_P024986 | 6.06 | 70 d | ||
| A_70_P003451 | 4.09 | 70 d | ||
| A_70_P046666 | 16.21 | 85 d | ||
| A_70_P063416 | 10.39 | 85 d | ||
| A_70_P037371 | 7.83 | 85 d | ||
| A_70_P054756 | 6.29 | 85 d | ||
| A_70_P055056 | 6.03 | 85 d | ||
| A_70_P050846 | 5.60 | 85 d | ||
| A_70_P019721 | 4.00 | 85 d | ||
| A_70_P017031 | 131.77 | 100 d | ||
| A_70_P044801 | 10.16 | 100 d | ||
| A_70_P024246 | 5.85 | 100 d | ||
| A_70_P057421 | 5.22 | 100 d | ||
| A_70_P070736 | 5.20 | 100 d | ||
| A_70_P011371 | 4.25 | 100 d | ||
| A_70_P017031 | 1389.16 | 120 d | ||
| A_70_P066011 | 670.44 | 120 d | ||
| A_70_P066386 | 76.81 | 120 d | ||
| A_70_P052621 | 14.06 | 120 d | ||
| A_70_P065251 | 9.68 | 120 d | ||
| A_70_P044801 | 7.26 | 120 d | ||
| A_70_P035891 | 5.93 | 120 d | ||
| A_70_P000126 | 4.97 | 120 d | ||
| A_70_P016471 | 4.40 | 120 d | ||
| A_70_P039346 | 4.32 | 120 d | ||
| A_70_P011531 | 4.14 | 120 d | ||
| A_70_P045436 | 4.13 | 120 d | ||
| A_70_P025036 | 11.22 | 135 d | ||
| A_70_P049266 | 7.06 | 135 d | ||
| A_70_P030156 | 4.28 | 135 d | ||
| A_70_P030132 | 4.20 | 135 d | ||
| A_70_P001016 | 3.52 | 135 d |
Differentially expressed probes were detected from five t-test analyses using GeneSpring 10.0 (Agilent Technologies).
1. Original probe name in the microarray analysis. 2. The GenBank Accession Number of expressed sequence tags provided by the manufacturer according to the specific probe name. 3. The highly homologous human sequences acquired by a BLASTN search in NCBI (search setting: query coverage not less than 50%, E-value less than 1.00E-100).
Validation of differential expression by quantitative PCR (qPCR)
| Ratio of gene expression between two sheep breeds1 | ||||||
|---|---|---|---|---|---|---|
| Gene | Method | T70/U70 | T85/U85 | T100/U100 | T120/U120 | T135/U135 |
| qPCR | 0.23 | 1.36 | 4.17 | 0.57 | 0.11 | |
| microarray | 8.92 | 16.21* | 1.78 | 0.78 | 0.98 | |
| qPCR | 131.73 | 382.54 | 35.06 | 2.3 | 1.16 | |
| microarray | 1.38 | 1.14 | 5.20* | 3.15 | 0.94 | |
| qPCR | 0.82 | 1.65 | 0.32 | 0.16 | 0.10 | |
| microarray | 1.10 | 1.11 | 0.34* | 0.88 | 0.87 | |
| qPCR | 6.64 | 21.65 | 0.51 | 0.78 | 0.16 | |
| microarray | 0.52 | 0.59 | 0.47* | 0.50 | 0.57 | |
| qPCR | 81.5 | 714.32 | 323.03 | 3.7 | 0.02 | |
| microarray | 2.80* | 3.52* | 1.54 | 1.15 | 0.80 | |
| qPCR | 0.29 | 0.87 | 1.48 | 0.17 | 0.84 | |
| microarray | 0.48* | 0.60 | 1.54 | 3.03 | 1.10 | |
| qPCR | 0.14 | 0.15 | 0.25 | 0.31 | 0.12 | |
| microarray | 0.49* | 0.61 | 1.02 | 0.75 | 1.20 | |
| qPCR | 0.06 | 0.30 | 0.85 | 1.11 | 0.42 | |
| microarray | 0.51 | 0.35 | 1.79 | 0.20* | 0.26 | |
| qPCR | 0.21 | 0.54 | 5.12 | 6.23 | 10.46 | |
| microarray | 0.88 | 0.69 | 0.41* | 0.62 | 1.78 | |
| qPCR | 0.61 | 0.44 | 0.23 | 1.06 | 0.29 | |
| microarray | 0.51 | 0.36* | 1.03 | 1.92 | 1.14 | |
| qPCR | 1.79 | 0.16 | 0.73 | 0.35 | 0.85 | |
| microarray | 1.09 | 0.55 | 0.48* | 1.39 | 0.47 | |
| qPCR | 0.35 | 1.0 | 3.44 | 0.84 | 0.85 | |
| microarray | 0.42* | 1.14 | 0.88 | 1.16 | 1.04 | |
| qPCR | 0.84 | 1.36 | 0.21 | 0.57 | 0.56 | |
| microarray | 1.89 | 5.60* | 1.56 | 1.19 | 1.09 | |
| qPCR | 0.51 | 0.76 | 0.56 | 0.07 | 2.79 | |
| microarray | 2.16 * | 2.31 | 1.23 | 0.82 | 0.72 | |
| qPCR | 0.81 | 0.71 | 0.54 | 0.47 | 0.61 | |
| microarray | 0.69 | 0.92 | 0.62 | 0.56 | 0.81 | |
1. The data in the rows are the ratio of the 2ΔΔCT values for the qPCR in a Texel sheep sample relative to that in the Ujumqin sheep sample at the same developmental stage. The microarray row provides gene expression ratios in Texel sheep samples divided by those in Ujumqin sheep samples at the same developmental stage. *Differentially expressed genes in the microarray analysis with a statistically significant difference at p < 0.05.